Differential effects of 17β-estradiol and raloxifene on bone and lipid metabolism in rats with chronic kidney disease and estrogen insufficiency

Menopause

Volumn 17, Issue 4, 2010, Pages 766-771

  Naves Díaz, Manuel ^a,b   Carrillo López, Natalia ^a,b   Rodríguez Rodríguez, Aránzazu ^a   Braga, Socorro ^a   Fernández Coto, Teresa ^a   Lopez Novoa, Jose Miguel ^b,c   López Hernández, Francisco ^b,d   Cannata Andía, Jorge B ^a,b  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^b Instituto Reina Sofía de Investigación   (Spain)

^c UNIVERSITY OF SALAMANCA   (Spain)

^d HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

17A estradiol; Chronic kidney disease; Estrogen insufficiency; Raloxifene; Rats

Indexed keywords

CALCITRIOL; CHOLESTEROL; ESTRADIOL; PLACEBO; RALOXIFENE; BONE DENSITY CONSERVATION AGENT; CALCIUM; ESTROGEN; PARATHYROID HORMONE; PHOSPHORUS; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE METABOLISM; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DRUG EFFECT; ESTROGEN DEFICIENCY; ESTROGEN THERAPY; FEMALE; HISTOPATHOLOGY; LIPID METABOLISM; MORPHOMETRICS; NEPHRECTOMY; NONHUMAN; OVARIECTOMY; RAT; TRABECULAR BONE; ANIMAL; ATROPHY; BLOOD; CHRONIC DISEASE; HYPERPLASIA; KIDNEY DISEASE; METABOLISM; ORGAN SIZE; PATHOLOGY; SPRAGUE DAWLEY RAT; TIBIA; UDDER; UTERUS;

ANIMALS; ATROPHY; BONE DENSITY CONSERVATION AGENTS; CALCITRIOL; CALCIUM; CHOLESTEROL; CHRONIC DISEASE; ESTRADIOL; ESTROGENS; FEMALE; HYPERPLASIA; KIDNEY DISEASES; MAMMARY GLANDS, ANIMAL; ORGAN SIZE; PARATHYROID HORMONE; PHOSPHORUS; RALOXIFENE; RATS; RATS, SPRAGUE-DAWLEY; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TIBIA; UTERUS;

EID: 77954954902     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e3181ce6874     Document Type: Article

References (41)

1. Cauley JA, Zmuda JM, Ensrud KE, Bauer DC, Ettinger B. Timing of estrogen replacement therapy for optimal osteoporosis prevention. J Clin Endocrinol Metab 2001;86:5700-5705.
2. Lindsay R. Hormones and bone health in postmenopausal women. Endocrine 2004;24:223-230.
3. Greendale GA, Gold EB. Lifestyle factors: are they related to vasomotor symptoms and do they modify the effectiveness or side effects of hormone therapy? Am J Med 2005;118:148-154.
4. Pinkerton JV, Dalkin AC. Combination therapy for treatment of osteoporosis: a review. Am J Obstet Gynecol 2007;197:559-565.
5. Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995;332:1589-1593.
6. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
7. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-1712.
8. Verkooijen HM, Bouchardy C, Vinh-Hung V, Rapiti E, Hartman M. The incidence of breast cancer and changes in the use of hormone re-placement therapy: a review of the evidence. Maturitas 2009;64:80-85.
9. Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997; 337:1641-1647.
10. Black LJ, Sato M, Rowley ER, et al. Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest 1994;93:63-69.
11. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006;295:2727-2741.
12. Goldstein SR, Duvernoy CS, Calaf J, et al. Raloxifene use in clinical practice: efficacy and safety. Menopause 2009;16:413-421.
13. Erben RG, Bromm S, Stangassinger M. Therapeutic efficacy of 1α,25-dihydroxyvitamin D3 and calcium in osteopenic ovariectomized rats: evidence for a direct anabolic effect of 1α,25-dihydroxyvitamin D3 on bone. Endocrinology 1998;139:4319-4328.
14. Naves Diaz M, Rodriguez Rodriguez A, Fernandez Martin JL, et al. Effects of estradiol, calcitriol and both treatments combined on bone histomorphometry in rats with chronic kidney disease and ovariectomy. Bone 2007;41:614-619.
15. Llach F, Velasquez Forero F. Secondary hyperparathyroidism in chronic renal failure: pathogenic and clinical aspects. Am J Kidney Dis 2001;38: S20-S33.
16. Slatopolsky E, Lopez-Hilker S, Delmez J, Dusso A, Brown A, Martin KJ. The parathyroid-calcitriol axis in health and chronic renal failure. Kidney Int 1990;29:S41-S47.
17. Moe S, Drueke T, Cunningham J, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006;69: 1945-1953.
18. Cheng S, Coyne D. Vitamin D and outcomes in chronic kidney disease. Curr Opin Nephrol Hypertens 2007;16:77-82.
19. Ginsburg ES, Owen WF Jr, Greenberg LM, Shea BF, Lazarus JM, Walsh BW. Estrogen absorption and metabolism in postmenopausal women with end-stage renal disease. J Clin Endocrinol Metab 1996;81: 4414-4417.
20. Weisinger JR, Gonzalez L, Alvarez H, et al. Role of persistent amenorrhea in bone mineral metabolism of young hemodialyzed women. Kidney Int 2000;58:331-335.
21. Holley JL, Schmidt RJ. Hormone replacement therapy in postmeno-pausal women with end-stage renal disease: a review of the issues. Semin Dial 2001;14:146-149.
22. Matuszkiewicz-Rowinska J, Skorzewska K, Radowicki S, et al. The benefits of hormone replacement therapy in pre-menopausal women with oestrogen deficiency on haemodialysis. Nephrol Dial Transplant 1999;14:1238-1243. (Pubitemid 29209314)
23. Hernandez E, Valera R, Alonzo E, et al. Effects of raloxifene on bone metabolism and serum lipids in postmenopausal women on chronic hemodialysis. Kidney Int 2003;63:2269-2274.
24. Brennan TC, Rizzoli R, Ammann P. Selective modification of bone quality by PTH, pamidronate or raloxifene. J Bone Miner Res 2009;24: 800-808.
25. Ormrod D, Miller T. Experimental uremia. Description of a model producing varying degrees of stable uremia. Nephron 1980;26:249-254.
26. Waynforth H. Ovariectomy, Experimental and Surgical Technique in the Rat. London, England: Harcourt Brace Jovanovich; 1980.
27. Rodriguez-Rodriguez A, Naves M, Rodriguez-Rebollar A, Gomez C, Braga S, Cannata-Andia JB. Hormonal replacement therapy in an animal model with chronic renal failure and ovariectomy: biochemical and densitometric study. Kidney Int Suppl 2003:S57-S61.
28. Parfitt AM. Bone histomorphometry: standardization of nomenclature, symbols and units. Summary of proposed system. Bone Miner 1988; 4:1-5.
29. Horowitz MC. Cytokines and estrogen in bone: anti-osteoporotic effects. Science 1993;260:626-627.
30. Kanatani M, Sugimoto T, Takahashi Y, Kaji H, Kitazawa R, Chihara K. Estrogen via the estrogen receptor blocks cAMP-mediated parathyroid hormone (PTH)-stimulated osteoclast formation. J Bone Miner Res 1998;13:854-862.
31. Carrillo-Lopez N, Roman-Garcia P, Rodriguez-Rebollar A, Fernandez-Martin JL, Naves-Diaz M, Cannata-Andia JB. Indirect regulation of PTH by estrogens may require FGF23. J Am Soc Nephrol 2009;20: 2009-2017.
32. Wassertheil-Smoller S, Hendrix SL, Limacher M, et al. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA 2003;289:2673-2684.
33. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523-534.
34. Takahashi F, Finch JL, Denda M, Dusso AS, Brown AJ, Slatopolsky E. A new analog of 1,25-(OH)2D3, 19-NOR-1,25-(OH)2D2, suppresses serum PTH and parathyroid gland growth in uremic rats without elevation of intestinal vitamin D receptor content. Am J Kidney Dis 1997;30:105-112.
35. Liel Y, Shany S, Smirnoff P, Schwartz B. Estrogen increases 1,25-dihydroxyvitamin D receptors expression and bioresponse in the rat duodenal mucosa. Endocrinology 1999;140:280-285.
36. Ten Bolscher M, Netelenbos JC, Barto R, Van Buuren LM, Van der vijgh WJ. Estrogen regulation of intestinal calcium absorption in the intact and ovariectomized adult rat. J Bone Miner Res 1999;14: 1197-1202.
37. Mathew S, Lund RJ, Chaudhary LR, Geurs T, Hruska KA. Vitamin D receptor activators can protect against vascular calcification. J Am Soc Nephrol 2008;19:1509-1519.
38. Majima T, Komatsu Y, Shimatsu A, et al. Clinical significance of 1-year treatment with raloxifene on bone and lipid metabolism in Japanese postmenopausal women with osteoporosis. Endocr J 2007;54:855-862.
39. Cano A, Dapia S, Noguera I, et al. Comparative effects of 17A-estradiol, raloxifene and genistein on bone 3D microarchitecture and volumetric bone mineral density in the ovariectomized mice. Osteoporos Int 2008;19:793-800.
40. Ishani A, Blackwell T, Jamal SA, Cummings SR, Ensrud KE. The effect of raloxifene treatment in postmenopausal women with CKD. J Am Soc Nephrol 2008;19:1430-1438
41. Introduction and definition of CKD-MBD and the development of the guideline statements. Kidney Int 2009;76:S3-S8.